Breast Cancer Clinical Trial

Apollo Device for Metastatic Breast Cancer (MBC)

Summary

This is a single-arm, open label pilot intervention study with outcomes measured by electronic survey and chart review evaluating a wearable device called Apollo, which is similar to a FitBit but emits vibrations. Our primary objective is to assess whether or not Apollo can help with symptoms of fatigue and pain in patients with Metastatic Breast Cancer (MBC).

View Full Description

Full Description

This study aims to provide preliminary data on the efficacy and tolerability of the Apollo device in the management of fatigue and pain in patients with Metastatic Breast Cancer (MBC).

Apollo is about the size of an Apple Watchand can be worn on the ankle, wrist, or armwith two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears. The scientific principles guiding the use of Apollo and mechanistic understanding of its effects on the body are consistent with the understanding of how music and therapeutic touch effect the body to convey feelings of energy, focus, or relaxation by sending safety signals to the emotional cortex (limbic system) in the brain. Similar to music and touch used to facilitate a healing response in the body, there are no known side effects to this type of therapy.

The PROMIS-Fatigue scale and the Functional Assessment of Cancer Therapy Fatigue (FACT-F) are instruments that have been previously validated in multiple diseases and will be used in this study. Preliminary data on indices of pain, use of PRN pain medications, health-related quality of life, sleep, anxiety and depression and tolerability/frequency of use with the Apollo device in MBC will also be evaluated using:

PROMIS pain scale
Use of pain medications
Health-related quality of life (HRQOL) using PROMIS-29
PROMIS Sleep
Hospital Anxiety and Depression Scale (HADS)
Usage data from Apollo app

This study aims to identify improvement of fatigue symptoms from baseline after 4 and 8 weeks of Apollo use. Improvements in pain, quality of life, use of PRN pain medication, anxiety and sleep.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Metastatic breast cancer diagnosis
Fatigue score of 4 or greater at last clinic visit

Exclusion Criteria:

Not able to read and understand English
Use of Beta Blockers,
Use of medications for serious mental illness

Study is for people with:

Breast Cancer

Estimated Enrollment:

30

Study ID:

NCT04983342

Recruitment Status:

Recruiting

Sponsor:

Margaret Quinn Rosenzweig

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Magee Womens Hospital
Pittsburgh Pennsylvania, 15213, United States More Info
Margaret Q Rosenzweig, PhD, CRNP
Contact
412-973-7131
[email protected]
Adam Brufsky, MD,PhD
Contact
412-641-4530
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

30

Study ID:

NCT04983342

Recruitment Status:

Recruiting

Sponsor:


Margaret Quinn Rosenzweig

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider